Richard Ronald 4
4 · Emergent BioSolutions Inc. · Filed Dec 9, 2025
Insider Transaction Report
Form 4
Richard Ronald
Director
Transactions
- Sale
Common Stock
2025-12-05$12.11/sh−7,100$85,990→ 98,417 total - Exercise/Conversion
Common Stock
2025-12-05$5.02/sh+25,748$129,255→ 124,165 total - Tax Payment
Common Stock
2025-12-05$11.90/sh−10,864$129,258→ 113,301 total - Sale
Common Stock
2025-12-05$11.90/sh−14,884$177,087→ 98,417 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-12-05−25,748→ 0 totalExercise: $5.02Exp: 2031-05-22→ Common Stock (25,748 underlying)
Footnotes (5)
- [F1]Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated.
- [F2]The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $12.11 to $12.12.
- [F3]Represents shares of common stock sold solely to satisfy the option exercise price and applicable taxes associated with the option exercise.
- [F4]The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $11.88 to $11.97.
- [F5]Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, as compensation for Board and Committee service. The shares underlying the options exercised were fully vested on May 22, 2025.